Protecting our Pharmaceutical Supply Chain from China Act of 2021
Latest action · Jul 28, 2021 Read twice and referred to the Committee on Finance.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJul 28, 2021
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Protecting our Pharmaceutical Supply Chain from China Act of 2021
This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.
The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.
Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.
The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.
Cosponsors 4
Members who signed on, in the order they did. All signed on Jul 28, 2021.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-TN | Marsha Blackburn | Original | Jul 28, 2021 |
| R-IN | Mike Braun | Original | Jul 28, 2021 |
| R-FL | Rick Scott | Original | Jul 28, 2021 |
| R-TX | Ted Cruz | Original | Jul 28, 2021 |
Actions 2
Everything that happened, newest first.
- Jul 28, 2021Introduced in Senate
- Jul 28, 2021Read twice and referred to the Committee on Finance.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 3401 | ABC Safe Drug Act | Related bill | Dec 15, 2021 |
| HR 7121 | Protecting our Pharmaceutical Supply Chain from China Act of 2022 | Related bill | Mar 28, 2022 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Asia
- Business expenses
- China
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Health
- Health care costs and insurance
- Health programs administration and funding
- Health technology, devices, supplies
- Income tax deductions
- Manufacturing
- Military medicine
- Military procurement, research, weapons development
- Prescription drugs
- Public contracts and procurement
- Trade restrictions
- Veterans' medical care
Text 1
Each version as it was printed, newest first.
- Jul 28, 2021Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.